This is a study of tramadol as an agent for short-term opioid withdrawal treatment. A
randomized, double blind clinical trial comparing the efficacy and safety of tramadol to
clonidine and buprenorphine in the short-term treatment of opioid withdrawal will be
conducted. Opioid dependent participants will be treated on a residential unit. The primary
outcome measure is opioid withdrawal symptoms.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Clonidine Naloxone Tramadol